Literature DB >> 3768535

A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia.

F Lemoine, A Najman, C Baillou, J Stachowiak, G Boffa, P Aegerter, L Douay, J P Laporte, N C Gorin, G Duhamel.   

Abstract

The diagnostic value in polycythemia of the presence of endogenous erythroid colonies derived from bone marrow cells (EECs) was assessed in a prospective study on 108 patients referred for polycythemia (Hb greater than g/dL in men, greater than 16 g/dL in women) with normal plasma volume by comparison with the standard criteria, the bone marrow grade, and the serum erythropoietin (Epo) level. Total red cell volume (TRCV) was high (greater than 36 mL/kg in men, 32 mL/kg in women) in 87 cases (group A) and slightly increased in 21 cases (group B). Standard criteria were applicable in 63 of 108 cases (57%); 46 were PV and 17 were secondary polycythemia (SP). Standard criteria were nonapplicable in 45 cases. EECs were present in 65 cases (60%) with a ratio of EEC/Epo-stimulated colonies of 39.5% +/- 18% (extremes 10% to 80%). EECs were noted in 43 of 46 polycythemia vera (PV) and 0 of 17 SP. Among the 45 unclassified cases, EECs were noted in 22: 18 of 29 cases from group A (10 with 2 major and 1 minor criteria; 8 with 2 major criteria) and 4 of 16 cases from group B (with variable standard criteria, 2 belonging to a PV family). In group A, there was a positive significant correlation between EECs and the presence of two major and 1 minor criteria (P less than .0001). In group B, there was a positive significant correlation between EECs and the presence of at least 1 major criterion and 2 minor criteria or a family background (P less than .0001). The unclassified polycythemias with EECs in the bone marrow are characterized by a bone marrow grade and a mean serum Epo level not different from that of patients with PV and an active course of the disease. The unclassified polycythemias without EECs in the bone marrow are a heterogeneous group corresponding in some cases to SPs of unknown origin (slightly increased bone marrow grade and/or high serum Epo level), and in others cases to spurious polycythemias (normal bone marrow grade and/or normal Epo level). In conclusion, EECs were of great value in differentiating PV from SP (P less than .001), and in allowing the diagnosis of PV in the absence of all the standard criteria even when TRCV was slightly increased. In our study, EEC improved the classification of polycythemia by 22%. The recommended diagnostic steps for the evaluation of polycythemia must be reconsidered.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3768535

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Erythroid colony growth from peripheral blood and bone marrow in polycythaemia.

Authors:  G S Masters; P Baines; A Jacobs
Journal:  J Clin Pathol       Date:  1990-11       Impact factor: 3.411

Review 2.  Rethinking the diagnostic criteria of polycythemia vera.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Leukemia       Date:  2013-12-19       Impact factor: 11.528

3.  Bone marrow tissue and proliferation markers: results and general problems.

Authors:  J Thiele; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

4.  JAK2V617F mutation in patients with portal vein thrombosis.

Authors:  Yusuf Bayraktar; Ozgur Harmanci; Yahya Büyükasik; Ali Ibrahim Shorbagi; Aysegul Hasegeli Sungur; Cemaliye Akyerli Boylu; Aytemiz Gürgey; Ferhun Balkanci
Journal:  Dig Dis Sci       Date:  2008-03-15       Impact factor: 3.199

5.  Behavior of hematopoietic stem cells in a large animal.

Authors:  J L Abkowitz; M T Persik; G H Shelton; R L Ott; J V Kiklevich; S N Catlin; P Guttorp
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

Review 6.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 7.  JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views.

Authors:  Naseema Gangat; Natasha Szuber; Animesh Pardanani; Ayalew Tefferi
Journal:  Leukemia       Date:  2021-05-21       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.